New shot aims to toughen fragile bones in rare disease

NCT ID NCT07557446

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This phase 2 trial tests a drug called AGA2115 in 48 Chinese adults and adolescents with osteogenesis imperfecta (types I, III, IV), a condition that makes bones brittle. Participants receive one of three dose schedules by injection under the skin. The study checks for side effects and measures changes in bone density over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
AGA2115 (a drug injected under the skin to strengthen bones)
What this could lead to
If successful, this could point toward a new treatment to improve bone density and reduce fractures in people with osteogenesis imperfecta.
What could go wrong
This is an early-phase trial with only 48 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve bone strength significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOGENESIS IMPERFECTA (OI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's Hospital of Soochow University

    NOT_YET_RECRUITING

    Suzhou, Jiangsu, 215025, China

  • Chinese Academy of Medical Sciences, Peking Union Medical College Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100005, China

  • Shanghai Sixth People's Hospital

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, 200233, China

  • The University of Hong Kong-Shenzhen Hospital

    RECRUITING

    Shenzhen, Guangdong, 518053, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.